Predictors of hypervirulent Klebsiella pneumoniae infections: a systematic review and meta-analysis
Background: Hypervirulent Klebsiella pneumoniae (hvKp) infections confer notable morbidity and mortality. Differential diagnosis to determine whether the infections are caused by either the hvKp or classical K. pneumoniae (cKp) strain is particularly important for undertaking optimal clinical care and infection control efforts. Aim: To identify and assess the potential predictors of hvKp infections. Methods: PubMed, Web of Science, and Cochrane Library databases were searched for all relevant publications from January 2000 to March 2022. The search terms included a combination of the following terms: (i) Klebsiella pneumon...
Source: Current Awareness Service for Health (CASH) - March 14, 2023 Category: Consumer Health News Source Type: news
A cross-sectional study of determinants of type 2 diabetes mellitus among professional drivers in the perambalur municipality area of Tamil Nadu, India - M T, Kulothungan K, Rizvana S, Thirunavukkarasu S.
Background Professional drivers have a powerful impact on public safety. They are also at a higher risk of obesity, hypertension, and type 2 diabetes mellitus (T2DM) because of their lifestyle. Diabetes and its complications can affect driving and cause in... (Source: SafetyLit)
Source: SafetyLit - March 9, 2023 Category: International Medicine & Public Health Tags: Distraction, Fatigue, Chronobiology, Vigilance, Workload Source Type: news
Clinically Relevant Benefits Seen for GLP-1RA, SGLTi Treatment of T1DM
THURSDAY, March 2, 2023 -- Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) are beneficial for treating type 1 diabetes mellitus (T1DM), with similar reductions in glycated hemoglobin A1c... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 2, 2023 Category: Pharmaceuticals Source Type: news
Assessing Pain Among Individuals Living With Dementia
During the early days of the COVID-19 pandemic, I received a telephone call from a caregiver in an assisted living facility with a request to restart quetiapine for a male resident living with severe dementia and type 2 diabetes mellitus. This resident had been successfully tapered off quetiapine nine months earlier. Although he had a history of psychotic symptoms and physical aggression, he had been both medically and behaviorally stable. (Source: Caring for the Ages)
Source: Caring for the Ages - March 1, 2023 Category: Health Management Authors: Elizabeth Galik Tags: Caring Collaborative Source Type: news
Pioglitazone Use Linked to Reduced Dementia Risk in T2DM
THURSDAY, Feb. 16, 2023 -- For patients with diabetes mellitus (DM), pioglitazone use is associated with a reduced risk for dementia, especially in those with a history of ischemic heart disease or stroke, according to a study published online Feb.... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 16, 2023 Category: Pharmaceuticals Source Type: news
Association of metformin use with fracture risk in type 2 diabetes: a systematic review and meta-analysis of observational studies - Wang Y, Yu L, Ye Z, Lin R, Sun ARJ, Liu L, Wei J, Deng F, Zhong X, Cui L, Li L, Liu Y.
AIMS: Increasing evidence suggests that metformin can affect bone metabolism beyond its hypoglycemic effects in diabetic patients. However, the effects of metformin on fracture risk in type 2 diabetes mellitus (T2DM) patients remain unclear. A systematic r... (Source: SafetyLit)
Source: SafetyLit - February 6, 2023 Category: International Medicine & Public Health Tags: Ergonomics, Human Factors, Anthropometrics, Physiology Source Type: news
Risk of fracture in adults with type 2 diabetes in Sweden: a national cohort study - Axelsson KF, Litsne H, Kousoula K, Franz én S, Eliasson B, Lorentzon M.
The objective of the study was to determine if patients with T2DM have increased fracture ri... (Source: SafetyLit)
Source: SafetyLit - February 6, 2023 Category: International Medicine & Public Health Tags: Ergonomics, Human Factors, Anthropometrics, Physiology Source Type: news
Presence of depression is associated with functional impairment in middle-aged and elderly Chinese adults with vascular disease/diabetes mellitus-a cross-sectional study - Zhao Y, Zhang Y, Teopiz KM, Lui LMW, McIntyre RS, Cao B.
OBJECTIVES: The association between chronic diseases and depression has received increasing attention, and are both considered to increase the risk of functional impairment. However, previous research evidence is controversial. Our study aimed to investiga... (Source: SafetyLit)
Source: SafetyLit - January 23, 2023 Category: International Medicine & Public Health Tags: Age: Elder Adults Source Type: news
In Diabetes, Women Have Higher Risk for Venous Thromboembolism
THURSDAY, Jan. 5, 2023 -- Individuals with diabetes mellitus (DM), especially women, have an increased risk for venous thromboembolism (VTE), according to a study published in the December issue of Diabetes Research and Clinical Practice.
Carola... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 5, 2023 Category: Pharmaceuticals Source Type: news
Glaring Link Between Statins And Alzheimer ’ s
Shocking new research suggests that Big Pharma’s drive to hook you on statin drugs could be a major culprit behind the explosion of Alzheimer’s cases across America and Europe.
I’m not surprised.
The medical establishment has been waging war against cholesterol for decades. Millions of people have been frightened into believing that high cholesterol levels equal heart disease – unless they follow doctors’ orders and pop statins every day.
Big Pharma has made billions from its cholesterol-busting stain industry. You may even have been bullied into taking mass-market statin drugs like Lipitor, Crestor, and Zocor yo...
Source: Al Sears, MD Natural Remedies - December 23, 2022 Category: Complementary Medicine Authors: Jacob Tags: Anti-Aging Brain Health Heart Health Source Type: news
Risk for T2DM Reduced With Higher Daily Step Count
TUESDAY, Dec. 20, 2022 -- Being more active is associated with a reduced risk for type 2 diabetes mellitus (T2DM), according to a study published online Dec. 2 in The Journal of Clinical Endocrinology& Metabolism.
Andrew S. Perry, M.D., from... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 20, 2022 Category: Pharmaceuticals Source Type: news
Racial/ethnic differences in associations between traumatic childhood experiences and both metabolic syndrome prevalence and type 2 diabetes mellitus risk among a cohort of US women - Gaston SA, Riley NM, Parks CG, Woo JMP, Sandler DP, Jackson CL.
OBJECTIVE: Childhood adversity has been associated with metabolic syndrome (MetS) and type 2 diabetes risk in adulthood. However, studies have yet to investigate traumatic childhood experiences (TCEs) beyond abuse and neglect (e.g., natural disaster) while... (Source: SafetyLit)
Source: SafetyLit - December 19, 2022 Category: International Medicine & Public Health Tags: Age: Adolescents Source Type: news
Low-Carbohydrate, High-Fat Diet Beneficial in T2DM in Short Term
MONDAY, Dec. 12, 2022 -- For individuals with type 2 diabetes mellitus (T2DM), a six-month, calorie-unrestricted low-carbohydrate, high-fat (LCHF) diet results in greater improvements in glycemic control and weight loss than a high-carbohydrate,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 12, 2022 Category: Pharmaceuticals Source Type: news
Real-World Study Shows Patients Treated with IMBRUVICA ® (ibrutinib) Were Less Likely to Initiate a Next-Line Treatment than Patients on Acalabrutinib in First-line Chronic Lymphocytic Leukemia
NEW ORLEANS, December 12, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results of a real-world study showing that patients with chronic lymphocytic leukemia (CLL) treated with first-line acalabrutinib monotherapy were 89 percent more likely to start a next-line treatment than those treated with IMBRUVICA® (ibrutinib).[1] These data suggest the potential that first-line treatment with IMBRUVICA® in routine practice may provide patients with the ability to use once-daily, all-oral IMBRUVICA® as a monotherapy treatment for a longer period without the need to start the next line of ...
Source: Johnson and Johnson - December 12, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
New Results from the Phase 3 GLOW Study of Fixed-Duration Treatment with IMBRUVICA ® (ibrutinib) Plus Venetoclax Demonstrate Robust Efficacy and Sustained Response in Older, Unfit Patients with Previously Untreated Chronic Lymphocytic Leukemia
NEW ORLEANS, December 10, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new four-year follow-up results from the Phase 3 GLOW study (Abstract #93), which showed investigational, fixed-duration treatment with IMBRUVICA® + venetoclax (I+V) reduced the risk of progression or death by 79 percent among older and/or unfit patients with previously untreated chronic lymphocytic leukemia (CLL) compared to patients treated with chemoimmunotherapy.[i] These results were highlighted in an oral presentation during the 2022 American Society of Hematology (ASH) Annual Meeting.1CLL is the most com...
Source: Johnson and Johnson - December 10, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
